시장보고서
상품코드
1842214

세계의 무균 배리어 시스템 시장 규모, 점유율, 동향 분석 : 제품별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Sterile Barrier Systems Market Size, Share & Trends Analysis Report By Product (Wraps, Rigid Containers, Pouches & Reels), By End Use (Hospitals, Ambulatory Surgery Centers, Outpatient Clinics), By Region, And Segment Forecasts, 2025 - 2033

발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

무균 배리어 시스템 : 시장 개요

세계의 무균 배리어 시스템 시장 규모는 2024년에 48억 4,000만 달러로 평가되었으며, 2033년에는 84억 5,000만 달러에 달하고, 2025년부터 2033년까지 CAGR은 6.52%로 성장할 것으로 예측됩니다.

세계 무균 배리어 시스템 시장은 의료 관련 감염(HAI)에 대한 인식 증가, 재활용, 생분해성, 재사용 가능한 재료에 대한 수요 증가, 기술 혁신 등으로 인해 크게 성장하고 있습니다.

또한, 병원 및 의료시설의 무균 시스템 도입이 증가하고 환자 안전에 대한 중요성이 강조되고 있는 것도 시장을 확대시키고 있습니다. 무균 의약품 및 생물학적 제제에 대한 수요 증가는 오염에 매우 민감하고 가장 엄격한 무균 조건에서 제조해야 하는 무균 배리어 시스템의 성장을 크게 촉진하고 있습니다. 비경구 의약품, 특히 주사제는 신체의 자연 방어 시스템을 우회하기 때문에 미생물 오염을 완전히 제거해야 합니다. 이러한 필요성 때문에 제약사들은 제품의 무결성을 유지하면서 무균성을 보장할 수 있는 첨단 멸균 솔루션에 투자하고 있습니다. 예를 들어, COVID-19 백신의 대량 생산은 기화 과산화수소(VH2O2)와 무균 충전 시스템을 신속하게 도입하여 전례 없는 무균 의약품 수요에 대응할 수 있음을 보여주었습니다.

또한, 만성질환의 증가, 노인 인구의 증가, 맞춤형 의료에 대한 수요 증가는 안전성과 유효성을 보장하기 위해 엄격한 무균 조건에서 제조 및 공급되어야 하는 주사제, 백신, 첨단 생물학적 치료제의 사용을 촉진하고 있습니다. 또한, 단클론항체, 세포 및 유전자 치료, mRNA 백신과 같은 생명공학 혁신은 제품의 무결성을 유지하기 위해 고도로 제어된 무균 환경과 특수 멸균 공정을 필요로 하며, 첨단 무균 제조 및 포장 솔루션에 대한 수요를 증가시키고 있습니다. 또한, 전 세계적으로 규제 당국의 감시가 강화되고 품질 기준이 엄격해짐에 따라 제조업체들은 규정을 준수하고 오염 위험을 줄이기 위해 효과적인 멸균 방법과 강력한 무균 장벽 시스템에 대한 투자를 확대할 수밖에 없습니다. 신뢰할 수 있는 무균 의약품 제조 및 포장 인프라에 대한 요구가 더욱 높아지고 있습니다.

또한, 수술기구 및 의료기기의 안전한 취급은 효과적인 무균 포장에 달려 있기 때문에 수술 건수의 증가는 무균 배리어 시스템 시장을 견인할 것으로 예상됩니다. 일부 의료 전문 분야에서는 수술 건수가 크게 증가한 것으로 보고되고 있습니다. 예를 들어, Procedural Statistics Release에 따르면, 2024년에는 약 1,585,878건의 성형수술이 이루어질 것으로 예상되며, 2023년 대비 1% 증가하였습니다. 또한, 재건 수술은 2% 증가하여 수술 건수의 전년 대비 꾸준한 성장을 반영하고 있습니다.

또한, 만성질환의 유병률 증가, 인구 고령화, 기존 수술과 최소침습 수술에 대한 수요 증가로 인해 병원과 수술 센터는 무균 기기의 안정적인 공급이 필요합니다. 파우치, 랩, 경질 용기 등의 무균 배리어 시스템은 미생물 오염을 방지하고 무균적인 체위를 보장하며 수술 부위 감염의 위험을 낮추기 위해 필요합니다. 엄격한 규제와 감염 제어 프로토콜은 고급 무균 장벽 솔루션의 채택을 강화하고 있습니다. 또한, 임플란트, 로봇기구 등 수술기구의 기술 혁신으로 특수 포장에 대한 요구가 더욱 높아지고 있습니다. 이러한 요인으로 인해 수술은 무균 배리어 시스템 시장의 직접적인 성장 촉진요인이 되고 있습니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 무균 배리어 시스템 시장 : 변수, 동향, 범위

  • 시장 연관 전망
    • 상부 시장 전망
    • 관련/부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
    • 시장 기회 분석
    • 시장 과제 분석
  • 무균 배리어 시스템 시장 : 분석 툴
    • 업계 분석 : Porter's Five Forces 분석
    • PESTEL 분석

제4장 무균 배리어 시스템 시장 : 제품별 추정·동향 분석

  • 무균 배리어 시스템 시장 : 제품별 대시보드
  • 무균 배리어 시스템 시장 : 변동 분석 : 제품별
  • 무균 배리어 시스템 시장 규모 및 예측·동향 분석 : 제품별(2021-2033년)
    • 경질 용기
    • 파우치 및 릴
    • 포장 삽입형 인디케이터

제5장 무균 배리어 시스템 시장 : 최종 용도별 추정·동향 분석

  • 무균 배리어 시스템 시장 : 최종 용도별 대시보드
  • 무균 배리어 시스템 시장 : 변동 분석 : 최종 용도별
  • 무균 배리어 시스템 시장 규모 및 예측·동향 분석 : 최종 용도별(2021-2033년)
    • 병원
    • 외래 수술 센터
    • 외래 진료소
    • 진단 검사실·영상 진단 센터
    • 장기간병 시설·요양원
    • 기타

제6장 무균 배리어 시스템 시장 : 지역별 추정·동향 분석(제품별, 최종 용도별, 지역별)

  • 세계의 무균 배리어 시스템 시장 : 지역별 대시보드
  • 시장 규모 예측과 동향 분석(2021-2033년)
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 스웨덴
    • 노르웨이
    • 덴마크
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 호주
    • 태국
    • 한국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 사우디아라비아
    • 남아프리카공화국
    • 아랍에미리트
    • 쿠웨이트

제7장 경쟁 구도

  • 주요 시장 진입 기업의 최근 동향과 영향 분석
  • 기업/경쟁 분류
    • 이노베이터
  • 벤더 상황
    • 주요 판매대리점·채널 파트너 리스트
    • 주요 기업의 시장 점유율 분석(2024년)
    • ASP
    • STERIS
    • 3M
    • Medline Industries, LP
    • Aesculap, Inc.-a B. Braun company
    • Cardinal Health
    • DePuy Synthes(Johnson & Johnson and its affiliates)
    • Case Medical
    • Wiicare(Wihuri Group)
    • Amcor
    • UFP Technologies, Inc.
    • Hermann Muller
    • ZUNO MEDICAL
    • ONE TRAY
    • Innovia Medical Company(Summit Medical LLC)
    • SAVUNA GmbH
    • STERIVIC Medical Co., Ltd
    • DuPont
KSM 25.11.13

Sterile Barrier Systems Market Summary

The global sterile barrier systems market size was estimated at USD 4.84 billion in 2024 and is projected to reach USD 8.45 billion by 2033, growing at a CAGR of 6.52% from 2025 to 2033. The global sterile barrier systems market is witnessing significant growth due to the growing awareness about healthcare-associated infections (HAIs), rising demand for recyclable, biodegradable, and reusable materials, and technological innovations.

In addition, the rising adoption of sterile systems in hospitals and healthcare facilities and a focus on patient safety are expanding the market. The increasing demand for sterile pharmaceuticals and biologics is significantly driving growth in the sterile barrier systems that are highly sensitive to contamination and require manufacturing under the most stringent sterility conditions. Parenteral drugs, especially injectable formulations, must be completely free of microbial contamination since they bypass the body's natural defense systems. This necessity is pushing pharmaceutical companies to invest in advanced sterilization solutions that can ensure sterility without compromising product integrity. For example, the large-scale production of COVID-19 vaccines demonstrated how vaporized hydrogen peroxide (VH2O2), and aseptic filling systems can be rapidly deployed to meet unprecedented sterile drug demand.

Moreover, the rise in chronic diseases, geriatric population, and growing demand for personalized medicine propels greater use of injectable drugs, vaccines, and advanced biologic therapies that must be manufactured and delivered under strict sterile conditions to ensure safety and efficacy. Furthermore, innovations in biotechnology, such as monoclonal antibodies, cell and gene therapies, and mRNA vaccines, require highly controlled aseptic environments and specialized sterilization processes to maintain product integrity, boosting demand for advanced sterile manufacturing and packaging solutions. In addition, heightened regulatory scrutiny and stringent quality standards worldwide are compelling manufacturers to invest more in validated sterilization methods and strong sterile barrier systems to meet compliance and reduce the risk of contamination. Further boosting the need for reliable sterile pharmaceutical manufacturing and packaging infrastructure.

Furthermore, the increasing volume of surgical procedures is anticipated to drive the sterile barrier systems market, as the safe handling of surgical instruments and medical devices depends on effective sterile packaging. Several medical specialties have reported significant growth in their surgical volume. For instance, the Procedural Statistics Release reported that around 1,585,878 cosmetic surgeries were performed in 2024, demonstrating a 1% increase from 2023. In addition, reconstructive procedures grew by 2%, reflecting steady year-on-year growth in surgical activity.

Moreover, with the rising prevalence of chronic diseases, an aging population, and growing demand for both traditional and minimally invasive surgeries, hospitals and surgical centers require a steady supply of sterile instruments. Sterile barrier systems, including pouches, wraps, and rigid containers, are necessary to prevent microbial contamination, ensure aseptic presentation, and lower the risk of surgical site infections. Stringent regulations and infection control protocols strengthen the adoption of advanced sterile barrier solutions. In addition, innovations in surgical devices such as implants and robotic instruments create further need for specialized packaging. These factors position surgical procedures as a direct growth driver for the sterile barrier systems market.

Global Sterile Barrier Systems Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global sterile barrier systems market report on the basis of product, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Wraps
  • Rigid Containers
  • Pouches & Reels
  • Indicators Embedded in Packaging
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Ambulatory Surgical Centers
  • Outpatient Clinics
  • Long-term Care Facilities & Nursing Homes"
  • Diagnostic Laboratories & Imaging Centers"
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Norway
    • Denmark
    • Sweden
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity price analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product type outlook
    • 2.2.2. Mounting type outlook
    • 2.2.3. Application outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Sterile Barrier Systems Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing demand for sterile pharmaceuticals and biologics
      • 3.2.1.2. Growth in the pharmaceutical and medical device industries
      • 3.2.1.3. Increase in surgical procedures and hospital infections prevention
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Limited material compatibility
      • 3.2.2.2. Product recalls
    • 3.2.3. Market Challenge Analysis
      • 3.2.3.1. Environmental concerns and sustainability issues
    • 3.2.4. Market Opportunity Analysis
      • 3.2.4.1. Technological innovation in materials
      • 3.2.4.2. Customization and advanced packaging solutions
      • 3.2.4.3. Integration with digital and smart technologies
  • 3.3. Sterile Barrier Systems Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Sterile Barrier Systems Market: Product Estimates & Trend Analysis

  • 4.1. Sterile Barrier Systems Market: Product Dashboard
  • 4.2. Sterile Barrier Systems Market: Product Movement Analysis
  • 4.3. Sterile Barrier Systems Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
    • 4.3.1. Wraps
      • 4.3.1.1. Wraps market estimates and forecast 2021 to 2033 (USD Million)
    • 4.3.2. Rigid Containers
      • 4.3.2.1. Rigid containers market estimates and forecast 2021 to 2033 (USD Million)
    • 4.3.3. Pouches & Reels
      • 4.3.3.1. Pouches & reels market estimates and forecast 2021 to 2033 (USD Million)
    • 4.3.4. Indicators Embedded in Packaging
      • 4.3.4.1. Indicators embedded in packaging market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Sterile Barrier Systems Market: End Use Estimates & Trend Analysis

  • 5.1. Sterile Barrier Systems Market: End Use Dashboard
  • 5.2. Sterile Barrier Systems Market: End Use Movement Analysis
  • 5.3. Sterile Barrier Systems Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
    • 5.3.1. Hospitals
      • 5.3.1.1. Hospitals market estimates and forecasts for 2021 to 2033 (USD Million)
    • 5.3.2. Ambulatory Surgical Centers
      • 5.3.2.1. Ambulatory surgical centers market estimates and forecast 2021 to 2033 (USD Million)
    • 5.3.3. Outpatient Clinics
      • 5.3.3.1. Outpatient clinics market estimates and forecast 2021 to 2033 (USD Million)
    • 5.3.4. Diagnostic Laboratories & Imaging Centers
      • 5.3.4.1. Diagnostic laboratories & imaging centers market estimates and forecast 2021 to 2033 (USD Million)
    • 5.3.5. Long-term Care Facilities & Nursing Homes
      • 5.3.5.1. Long-term care facilities & nursing homes market estimates and forecast 2021 to 2033 (USD Million)
    • 5.3.6. Others
      • 5.3.6.1. Others market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Sterile Barrier Systems Market: Regional Estimates & Trend Analysis by Product, End Use, and Region

  • 6.1. Global Sterile Barrier Systems Market: Regional Dashboard
  • 6.2. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 6.3. North America
    • 6.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement scenario
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. U.S. market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement scenario
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Canada market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.4. Mexico
      • 6.3.4.1. Key country dynamics
      • 6.3.4.2. Regulatory framework/ reimbursement scenario
      • 6.3.4.3. Competitive scenario
      • 6.3.4.4. Mexico market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.4. Europe
    • 6.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 6.4.2. UK
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement scenario
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. UK market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement scenario
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. Germany market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement scenario
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. France market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement scenario
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Italy market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement scenario
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Spain market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement scenario
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement scenario
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Norway market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.9. Denmark
      • 6.4.9.1. Key country dynamics
      • 6.4.9.2. Regulatory framework/ reimbursement scenario
      • 6.4.9.3. Competitive scenario
      • 6.4.9.4. Denmark market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement scenario
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.5.3. Japan
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement scenario
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Japan market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement scenario
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. India market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement scenario
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Australia market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement scenario
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.5.7. South Korea
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework/ reimbursement scenario
      • 6.5.7.3. Competitive scenario
      • 6.5.7.4. South Korea market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement scenario
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Brazil market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement scenario
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Argentina market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7. MEA
    • 6.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement scenario
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.7.3. South Africa
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement scenario
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. South Africa market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement scenario
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. UAE market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement scenario
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Kuwait market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Innovators
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key company market share analysis, 2024
    • 7.3.3. ASP
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. STERIS
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. 3M
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Medline Industries, LP
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Aesculap, Inc. - a B. Braun company
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Cardinal Health
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. DePuy Synthes (Johnson & Johnson and its affiliates)
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Case Medical
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Wiicare (Wihuri Group)
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Amcor
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. UFP Technologies, Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Hermann Muller
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. ZUNO MEDICAL
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Product benchmarking
      • 7.3.15.4. Strategic initiatives
    • 7.3.16. ONE TRAY
      • 7.3.16.1. Company overview
      • 7.3.16.2. Financial performance
      • 7.3.16.3. Product benchmarking
      • 7.3.16.4. Strategic initiatives
    • 7.3.17. Innovia Medical Company (Summit Medical LLC)
      • 7.3.17.1. Company overview
      • 7.3.17.2. Financial performance
      • 7.3.17.3. Product benchmarking
      • 7.3.17.4. Strategic initiatives
    • 7.3.18. SAVUNA GmbH
      • 7.3.18.1. Company overview
      • 7.3.18.2. Financial performance
      • 7.3.18.3. Product benchmarking
      • 7.3.18.4. Strategic initiatives
    • 7.3.19. STERIVIC Medical Co., Ltd
      • 7.3.19.1. Company overview
      • 7.3.19.2. Financial performance
      • 7.3.19.3. Product benchmarking
      • 7.3.19.4. Strategic initiatives
    • 7.3.20. DuPont
      • 7.3.20.1. Company overview
      • 7.3.20.2. Financial performance
      • 7.3.20.3. Product benchmarking
      • 7.3.20.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제